Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)
Abstract Background The REVOLENS study compared lung volume reduction coil treatment to usual care in patients with severe emphysema at 1 year, resulting in improved quality-adjusted life-year (QALY) and higher costs. Durability of the coil treatment benefit and its cost-effectiveness at 2 years are...
Main Authors: | Julie Bulsei, Sylvie Leroy, Jeanne-Marie Perotin, Hervé Mal, Charles-Hugo Marquette, Hervé Dutau, Arnaud Bourdin, Jean-Michel Vergnon, Christophe Pison, Romain Kessler, Vincent Jounieaux, Mathieu Salaün, Armelle Marceau, Sylvain Dukic, Coralie Barbe, Margaux Bonnaire, Gaëtan Deslee, Isabelle Durand-Zaleski, the REVOLENS study group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-018-0796-x |
Similar Items
-
Do We Need to Assess Quality-of-Life with Both the St George’s Respiratory Questionnaire and the EuroQol 5-Dimension Questionnaire in a Clinical Study with an Economic Component: Insights from the REVOLENS Study in Severe Emphysema
by: Bulsei J, et al.
Published: (2020-01-01) -
Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency
by: Perotin JM, et al.
Published: (2018-11-01) -
The Great I-QALY Disaster
by: Paul Langley
Published: (2020-08-01) -
EVALUATION OF INGUINAL REPAIR EFFECTIVENESS BASED ON «COST-UTILITY» ANALYSIS
by: A. N. Poborskiy, et al.
Published: (2019-02-01) -
The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER)
by: Paul Langley
Published: (2020-09-01)